TopoTarget successfully completes phase II/III trial with Savene  

2005.06.30
Danish biopharmaceutical company TopoTarget has successfully completed a phase II/III trial with Savene, the company's most advanced drug

TopoTarget, a Danish biopharmaceutical company which gained a listing on the Copenhagen Stock Exchange two weeks ago, has announced that it has successfully completed a phase II/III trial with Savene, the company's most advanced drug. Savene can be used as an antidote in situations where a widely used class of intravenously injected anti-cancer drugs (anthracyclines) may be accidentally infused outside a vein.

Peter Buhl Jensen, managing director of TopoTarget has previously been reported as saying that the potential global market for Savene is worth USD 60 mn (DKK 370.8 mn) annually. In relation to the successfully completed trial, he comments that it confirms the company's belief that Savene will gain marketing approval by the end of 2006. The news is reported by news agency direkt-dk and on TopoTarget's website.

TopoTarget was established in 2000 and has grown both organically and through acquisitions. In 2002, the company acquired the UK cell cycle company Profilix, and in 2005 the German company G2M Cancer Drugs. TopoTarget is headquartered in Copenhagen and has subsidiaries in Oxford UK, and Frankfurt Germany.

Link > TopoTarget 

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×